{
  "abstract": "Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with most patients diagnosed at an advanced stage. Atezolizumab plus bevacizumab is a current standard first-line therapy; however, outcomes are strongly influenced by underlying cirrhosis and clinically significant portal hypertension (CSPH). Complications such as ascites and variceal bleeding may limit treatment continuation, particularly as bevacizumab increases bleeding risk. Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal pressure and may improve outcomes, but its role in patients receiving immunoncology-based systemic therapy remains unclear.\n\nMethods: NISTIPS TRITICC-4 is a prospective, multicentre, non-interventional cohort study conducted at up to 25 centers in Germany. A total of 350 adult patients with cirrhosis and unresectable or metastatic HCC receiving first-line atezolizumab plus bevacizumab will be enrolled. Patients are allocated to two cohorts: TIPS in situ plus atezolizumab and bevacizumab or atezolizumab plus bevacizumab alone, according to routine clinical practice.\n\nThe primary endpoint is time to deterioration of liver function (TTDL), defined as persistent worsening of liver parameters for >4 weeks. Secondary endpoints include overall survival, time on treatment, overall response rate, time to new extrahepatic lesions or death, and safety with focus on bleeding and TIPS-related complications.\n\nTime-to-event endpoints will be analyzed using Kaplan–Meier methods and Cox models. Propensity score matching will be applied to adjust for confounding. Analyses are exploratory.\n\nDiscussion: This study will provide real-world evidence on the impact of TIPS in HCC patients receiving atezolizumab plus bevacizumab and may support more individualized management strategies in this high-risk population.\n\nClinical trial registration: www.clinicaltrials.gov identifier is NCT07365930",
  "abstract_shown": true,
  "affiliations": [
    "Clinic for Gastroenterology, Hepatology & Infectious Diseases, University Hospital of Düsseldorf, Düsseldorf, Germany",
    "Center for Integrated Oncology - Aachen Bonn Cologne Duesseldorf (CIO-ABCD), Duesseldorf, Germany",
    "Hospital Northwest, University Cancer Center Frankfurt, Frankfurt, Germany",
    "The Frankfurt Institute of Clinical Cancer Research IKF GmbH, Frankfurt am Main, Germany",
    "Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany",
    "Medical Department III, University Hospital of Aachen, Aachen, Germany",
    "Center for Integrated Oncology - Aachen Bonn Cologne Duesseldorf (CIO-ABCD), Aachen, Germany",
    "Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany",
    "Department of Medicine II, University Hospital, LMU Munich, Munich, Germany",
    "Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany",
    "Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases University Hospital Regensburg, Regensburg, Germany",
    "Cancer Center Esslingen, Klinikum Esslingen, Germany",
    "Department of Internal Medicine B, University Hospital Münster, Münster, Germany",
    "Department of Gastroenterology and Hepatology, Essen University Hospital, Essen, Germany",
    "Department of Medicine IV, Gastroenterology, Hepatology and Infectious Diseases, Heidelberg University, Heidelberg, Germany",
    "German Cancer Research Center (DKFZ) Heidelberg, Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany",
    "Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-University Medicine, Berlin, Germany",
    "TUM School of Medicine and Health, Department for Internal Medicine II, Technical University of Munich, TUM University Hospital, Munich, Germany"
  ],
  "article_type": "methods article",
  "arxiv": null,
  "author_total": 25,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Carolin Angendohr"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Christian Weigel"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Anselm Kunstein"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Markus Joerdens"
    },
    {
      "affs": [
        2,
        3
      ],
      "name": "Thorsten Goetze"
    },
    {
      "affs": [
        2,
        3
      ],
      "name": "Salah-Eddin Al-Batran"
    },
    {
      "affs": [
        3
      ],
      "name": "Bianca Zäpf"
    },
    {
      "affs": [
        4
      ],
      "name": "Maria Gonzalez-Carmona"
    },
    {
      "affs": [
        5,
        6
      ],
      "name": "Cennet Sahin"
    },
    {
      "affs": [
        5,
        6
      ],
      "name": "Marie-Luise Berres"
    },
    {
      "affs": [
        7
      ],
      "name": "Friedrich Foerster"
    },
    {
      "affs": [
        8
      ],
      "name": "Najib Ben Khaled"
    },
    {
      "affs": [
        9
      ],
      "name": "Christine Koch"
    },
    {
      "affs": [
        10
      ],
      "name": "Arne Kandulski"
    },
    {
      "affs": [
        11
      ],
      "name": "Henning Wege"
    },
    {
      "affs": [
        12
      ],
      "name": "Jonel Trebicka"
    },
    {
      "affs": [
        13
      ],
      "name": "Leonie S. Jochheim"
    },
    {
      "affs": [
        14,
        15
      ],
      "name": "Michael T. Dill"
    },
    {
      "affs": [
        14
      ],
      "name": "Christoph Springfeld"
    },
    {
      "affs": [
        16
      ],
      "name": "Severin Daum"
    },
    {
      "affs": [
        16
      ],
      "name": "Christoph Treese"
    },
    {
      "affs": [
        17
      ],
      "name": "Ursula Ehmer"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Tom Luedde"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Johannes Bode"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Christoph Roderburg"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5cba5t75vrrsh.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2748246",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757585/",
  "id": "5cba5t75vrrsh",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2748246",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Clinical Trial Protocol"
    ],
    [
      "heading",
      "Method"
    ],
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7223101032",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2748246?needAccess=true",
  "pmcid": "PMC13757585",
  "pmid": "42902603",
  "published": "2026-10-20",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/5cba5t75vrrsh.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:11Z",
      "native_id": "PMC13757585",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2748246"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)",
  "title_text": "Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:11Z",
  "url": "https://research.draconitic.com/paper/5cba5t75vrrsh",
  "venue": "Future Oncology",
  "versions": []
}